PUBLICATIONS

The 2022 ITAC evidence-based clinical practice guidelines: New update from the International Initiative on Thrombosis and Cancer to improve the care in patients with cancer-associated thrombosis. Frere C, Farge D, Douketis J, Connors JM. J Med Vasc. 2022; 47: 113-115. [DOI: 10.1016/j.jdmv.2022.08.002].

Comparison of the Khorana, PROTECHT and ONKOTEV risk assessment models to predict venous thromboembolism in patients with pancreatic cancer [abstract]. Frere C, Gauthier L, Canivet C, Gourgou S, Buscail L, Bournet B, Farge D. https://abstracts.isth.org/abstract/comparison-of-the-khorana-protecht-and-onkotev-risk-assessment-models-to-predict-venous-thromboembolism-in-patients-with-pancreatic-cancer/. Accessed August 28, 2022.

The Ottawa Score did not predict recurrent venous thromboembolism in the prospective TROPIQUE cohort study [abstract]. Frere C, Debourdeau P, lamblin A, Cajfinger F, Falvo N, Benhamou Y, Sevestre M, Farge D. https://abstracts.isth.org/abstract/the-ottawa-score-did-not-predict-recurrent-venous-thromboembolism-in-the-prospective-tropique-cohort-study/. Accessed August 28, 2022.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Munoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J, and the International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Lancet Oncology. July, 2022. DOI:https://doi.org/10.1016/S1470-2045(22)00160-7.

A review of latest clinical practice guidelines for the management of cancer-associated thrombosis. Frere C, Wahl C, Rueda-Camino JA, Crichi B, Prata PH, Marjanovic Z, Farge D. Best Pract Res Clin Haematol. 2022 May 28. Online ahead of print. doi.org/10.1016/j.beha.2022.101348

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. Trujillo-Santos J, Farge-Bancel D, Pedrajas JM, Gómez-Cuervo C, Ballaz A, Braester A, Mahé I, Villalobos A, Porras JA, Monreal M; RIETE Investigators. Res Pract Thromb Haemost. 2022 Jun 3;6(4):e12736. doi: 10.1002/rth2.12736.

Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. Frere C, Farge D, Schrag D, Prata PH, Connors JM. J Hematol Oncol. 2022 May 21;15(1):69. doi: 10.1186/s13045-022-01289-1.

Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study. Frere C, Crichi B, Rueda-Camino J, Cajfinger F, Spiess N, Janus N, Le Maignan C, Marjanovic Z, Farge D. J Med Vasc. 2022 May 20. Online ahead of print. [DOI: 10.1016/j.jdmv.2022.04.004]

Outcome of cancer-associated venous thromboembolism is more favorable among patients with hematologic malignancies than in those with solid tumors. Lecumberri R, Ruiz-Artacho P, Tzoran I, Brenner B, Farge Bancel D, Ay C, Rosa V, Iria F, Hernández-Blasco L, Trujillo Santos J, Monreal M. Thromb Haemost. 2022 Feb 21. doi: 10.1055/a-1777-4006. Epub ahead of print.

Direct Oral Anticoagulant Versus Low Molecular Weight Heparin for the Treatment of Cancer-Associated Thromboembolism: 2021 Updated Meta-Analysis of Randomized Controlled Trials. Frere C, Farge D, Schrag D, Prata PH P, Connors JM. Blood 2021; 138 (Supplement 1): 668. doi: https://doi.org/10.1182/blood-2021-150696

Patient education program at the forefront of cancer-associated thrombosis care. Sebuhyan M, Crichi B, Deville L, Le Maignan C, Bonnet C Marjanovic Z, Rueda J, Bensaoula O, Ndour A, Frere C, Madeleine I, Farge D. J Med Vasc. 2021 Aug 25. Online ahead of print. [DOI: 10.1016/j.jdmv.2021.08.001]

Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study. Benzidia I, Crichi B, Montlahuc C, Rafii H, N’Dour A, Sebuhyan M, Gauthier H, Ait Abdallah N, Benillouche P, Villiers S, Le Maignan C, Farge D. J Thromb Thrombolysis. 2021 Jul 22. Online ahead of print. [DOI: 10.1007/s11239-021-02512-5]

Development of a Multi-language Mobile App to Implement the 2019 ITAC Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Cancer Patients. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss (in memoriam) S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J. Res Pract Thromb Haemost. 2021; 5 (Suppl 1).
The Burden of Venous Thromboembolism in Pancreatic Cancer. Frere C, on behalf of the Groupe Francophone Thrombose et Cancer. World J Gastroenterol 2021; 27(19): 2325-2340 [DOI: 10.3748/wjg.v27.i19.2325]

Incidence, predictors and clinical outcomes of venous thromboembolism in patients with newly diagnosed pancreatic ductal adenocarcinoma: results of the prospective BACAP-VTE study. Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D on behalf of the Groupe Francophone Thrombose et Cancer and the BACAP Consortium. Thromb Res. 2021 Mar; 200 Suppl 1:S4. doi.org/10.1016/S0049-3848(21)00146-8

Update on Guidelines for the Management of Cancer-Associated Thrombosis. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Oncologist. 2021 Jan;26(1):e24-e40. doi: 10.1002/onco.13596.

What is the current state of thrombosis treatment and prevention in cancer patients? Farge D. J Med Vasc. 2020 Nov;45(6S):6S1-6S2. doi: 10.1016/S2542-4513(20)30512-5.

How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. Crichi B, Sebuhyan M, Abdallah NA, Montlahuc C, Bonnet C, Villiers S, Maignan CL, Yannoutsos A, Farge D. J Med Vasc. 2020 Nov;45(6S):6S24-6S30.

Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. Sebuhyan M, Crichi B, Abdallah NA, Bonnet C, Deville L, Marjanovic Z, Farge D. J Med Vasc. 2020 Nov;45(6S):6S31-6S38. doi: 10.1016/S2542-4513(20)30517-4. doi: 10.1016/S2542-4513(20)30516-2.

Management of Cancer-Associated Thrombosis: An Evolving Area. Frere C, Connors JM, Farge D. Cancers (Basel). Cancers 2020, October; 12(10), 2999; oi.org/10.3390/cancers12082028

Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frere C, Crichi B, Bournet B, Canivet C, AIt Abdallah N, Buscail L, Farge D. Cancers (Basel). Cancers 2020, July; 12(8), 2028; doi.org/10.3390/cancers12082028

Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D; BACAP Consortium. Gastroenterology. 2020 Apr;158(5):1346-1358.e4. doi: 10.1053/j.gastro.2019.12.009.

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented. Farge D, Bournet B, Conroy T, Vicaut E, Rak J, Zogoulous G, Barkun J, Ouaissi M, Buscail L, Frere C. Cancers (Basel). 2020 Mar 6;12(3). pii: E618. doi: 10.3390/cancers12030618.

Primary prophylaxis of venous thromboembolism in extragonadal germ-cell tumour. Kubicek P, Boughalem E, Frere C. J Med Vasc. 2020 Apr;45(2):90-92. doi: 10.1016/j.jdmv.2020.01.152.

Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. Rafii H, Frere C, Benzidia I, Crichi B, Andre T, Assenta E, Bournet B, Carpentier A, Connault J, Doucet L, Durant C, Emmerich J, Gris JC, Hij A, Le Hello C, Madeleine I, Messas E, N(Dour A, Villiers S, Marjanovic Z, Ait Abdallah N, Yannoutsos A, Farge D. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). J Med Vasc. 2020 Feb;45(1):28-40. doi: 10.1016/j.jdmv.2019.12.004

New progress in the treatment and prophylaxis of venous thrombo-embolism in cancer patients.
Connors JM, Farge D. J Med Vasc. 2020 Feb;45(1):2. doi: 10.1016/j.jdmv.2019.12.005

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 Lancet Oncol. 2019 Sep 3. pii: S1470-2045(19)30336-5. doi: 10.1016/S1470-2045(19)30336-5.

Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies. Frere C, Lejeune M, Kubicek P, Faille D, Marjanovic Z; and the Groupe Francophone Thrombose et Cancer. Cancers (Basel). 2019 Oct 24;11(11). pii: E1639. doi: 10.3390/cancers11111639.

Women, thrombosis, and cancer. Farge D, Le Maignan C, Doucet L, Frere C. Thromb Res. 2019 Sep;181 Suppl 1:S47-S53. doi: 10.1016/S0049-3848(19)30367-6.

Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges. Farge D, Frere C. F1000 Research 2019, 8(F1000 Faculty Rev):974

Prediction of early mortality in patients with cancer-associated thrombosis in the RIETE database.
Fuentes HE, Tafur AJ, Caprini JA, Alatri A, Trujillo-Santos J, Farge-Bancel D, Rosa V, Font L, Vilaseca A, Monreal M; RIETE Investigators. Int Angiol. 2019 May 16. doi: 10.23736/S0392-9590.19.04110-5

Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges.  Frere C, Benzidia I, Marjanovic Z, Farge D.Cancers (Basel). 2019 Jan 10;11(1). pii: E71. doi: 10.3390/cancers11010071.

The best direct-acting oral anticoagulant for treatment of venous thromboembolism? Frere C, Farge D. Lancet Haematol. 2018 Dec 14. pii: S2352-3026(18)30211-4. doi: 10.1016/S2352-3026(18)30211-4.

Factors influencing patient’s perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study. Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N, Ghiringhelli F, Hamadé A, Vedrine L, Farge D. Support Care Cancer. 2019 May 1. doi: 10.1007/s00520-019-04815-z.

Treatment of cancer associated thrombosis: Which role for direct oral anticoagulants in 2018? Frere C, Farge D. J Med Vasc. 2018 Sep;43(5):293-301.

Edoxaban for Cancer-Associated Venous Thromboembolism. Frere C, Dufilho M. N Engl J Med. 2018 Jul 5;379(1):94. doi: 10.1056/NEJMc1806646.

Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC). Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, Védrine L, Bensalha H, Bonnet I, Péré-Vergé D, Coudurier M, Li V, Rafii H, Benzidia I, Connors JM,* and Resche-Rigon M. Oncotarget. 2018; 9:26990-26999.

Clinical Course of Venous Thromboembolism in Patients with Pancreatic Cancer: Insights from the RIETE Registry. Frere C, Trujillo-Santos J, Font C, Sampériz Á, Quintavalla R, González-Martínez J, Vázquez FJ, Lima J, Farge D, Monreal M; RIETE Investigators. Thromb Haemost. 2018 Apr 21. doi: 10.1055/s-0038-1642009.

Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism.
Kuperman A, Lopez-Reyes R, Bosco LJ, Lorenzo A, Jose B, Farge-Bancel D, Alfonso M, Lumbierres M, Stemer G, Monreal Bosch M, Braester A; RIETE Investigators. J Thromb Thrombolysis. 2018 Jan 30. doi: 10.1007/s11239-018-1610-9.

Venous thromboembolism and pancreatic cancer. Frere C, Bournet B, Benzidia I, Jamelot M, Debourdeau P, Hij A, Rafii-Elayoubi A, Buscail L, Farge D, pour le Groupe francophone thrombose et cancer. J Med Vasc. 2018 In Press. doi: 10.1016/j.jdmv.2018.05.003

Risk of Arterial Thrombosis in Cancer Patients: Which Role for Cancer Therapies Vascular Toxicities? Frere C, Martin-Toutain I, Thuny F, Bonello L. J Am Coll Cardiol. 2018 Jan 16;71(2):260. doi: 10.1016/j.jacc.2017.10.087.

New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application. Benzidia I, Connault J, Solanilla A, Michon-Pasturel U, Jamelot M, Nguessan MK, Hij A, Le Maignan C, Farge D, Frère C; pour le Groupe Francophone Thrombose et Cancer. J Med Vasc. 2017 Dec;42(6):375-383. doi:10.1016/j.jdmv.2017.09.006

Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS study. Debourdeau P, Espié M, Chevret S, Gligorov J, Elias A, Dupré PF, Desseaux K, Kalidi I, Villiers S, Giachetti S, Frere C, Farge D. Cancer Med. 2017 Oct 4. doi: 10.1002/cam4.1201.

Implementation of international good clinical practice guidelines to improve care of patients with cancer-related venous thromboembolism. Qari R, Frere C, Farge D, El Ayoubi H. Journal of Applied Hematology. 2017. 8; 42 (3) : 85-98.doi: 10.4103/joah.joah_32_17

Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MP, Büller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M.Eur Heart J. 2017 Feb 17. doi: 10.1093/eurheartj/ehx003.

Women, thrombosis, and cancer: A gender-specific analysis. Farge D, Bounameaux H, Bauersachs RM, Brenner B. Thromb Res. 2017 Mar;151 Suppl 1:S21-S29. doi: 10.1016/S0049-3848(17)30062-2.

Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. Trujillo-Santos J, Martos FM, Font C, Farge-Bancel D, Rosa V, Lorenzo A, Barrón M, Lorente MA, Pedrajas JM, Monreal M. Heliyon. 2017 Jan 16;3(1):e00229. doi: 10.1016/j.heliyon.2016.e00229.

International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016 Oct;17(10):e452-e466. doi: 10.1016/S1470-2045(16)30369-2. PMID: 27733271.

Major bleeding complications in patients treated with direct oral anticoagulants: One-year observational study in a Paris Hospital. Deville L, Konan M, Hij A, Goldwirt L, Peyrony O, Fieux F, Faure P, Madelaine I, Villiers S, Farge-Bancel D, Frere C. Curr Res Transl Med. 2016 Jul-Sep;64(3):129-133. doi: 10.1016/j.retram.2016.02.003.

Clinical practice guidelines for prophylaxis of venous thomboembolism in cancer patients. Frere C, Farge D. Thromb Haemost. 2016 Sep 27;116(4):618-25. doi: 10.1160/TH16-04-0302

Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. Cajfinger F, Debourdeau P, Lamblin A, Benatar V, Falvo N, Benhamou Y, Sevestre MA, Farge-Bancel D; TROPIQUE investigators. Thromb Res. 2016 Aug;144:85-92. doi: 10.1016/j.thromres.2016.06.005.

Prophylaxis of venous thromboembolism in cancer patients. Frere C, Doucet L, Farge D.Expert Rev Hematol. 2016 Jun;9(6):535-9. doi: 10.1586/17474086.2016.1172959.

Role of platelets in cancer and cancer-associated thrombosis: Experimental and clinical evidences. Mezouar S, Frere C, Darbousset R, Mege D, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C.
Thromb Res. 2016 Mar;139:65-76.

Microparticles and cancer thrombosis in animal models. Mege D, Mezouar S, Dignat-George F, Panicot-Dubois L, Dubois C. Thromb Res. 2016 Apr;140 Suppl 1:S21-6.

ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.
Pepin M, Kleinjan A, Hajage D, Büller HR, Di Nisio M, Kamphuisen PW, Salomon L, Veyradier A, Stepanian A, Mahe I. J Thromb Haemost. 2016 Feb;14(2):306-15. doi: 10.1111/jth.13205.

The origin and concentration of circulating microparticles differ according to cancer type and evolution: A prospective single-center study. Mege D, Panicot-Dubois L, Ouaissi M, Robert S, Sielezneff I, Sastre B, Dignat-George F, Dubois C. Int J Cancer. 2016 Feb 15;138(4):939-48. doi: 10.1002/ijc.29837.

Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. Farge D, Trujillo-Santos J, Debourdeau P, Bura-Riviere A, Rodriguez-Beltrán EM, Nieto JA, Peris ML, Zeltser D, Mazzolai L, Hij A, Monreal M; RIETE Investigators.
Medicine (Baltimore). 2015 Aug;94.

Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Int. J. Cancer. 2015; Jan 15;136(2):462-75.

Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice. Thomas GM, Brill A, Mezouar S, Crescence L, Gallant M, Dubois C, Wagner DD. J Thromb Haemost. 2015 Jul;13:1310-9.

Involvement of platelet-derived microparticles in tumor progression and thrombosis. Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, Panicot-Dubois L, Dubois C. Semin Oncol. 2014 Jun;41(3):346-58. doi: 10.1053/j.seminoncol.2014.04.010.

Implementing thrombosis guidelines in cancer patients: a review. Farge-Bancel D, Bounameaux H, Brenner B, Büller HR, Kakkar A, Pabinger I, Streiff M, Debourdeau P. Rambam Maimonides Med J. 2014 Oct 29;5(4):e0041. doi: 10.5041/RMMJ.10175.

Therapy for cancer-related thromboembolism. Frere C, Debourdeau P, Hij A, Cajfinger F, N’Guessan M, Panicot-Dubois L, Dubois C, Farge D. Semin Oncol. 2014 Jun;41(3):319-38.

Prevention of VTE in Cancer Outpatients: guidance from the SSC of the ISTH. Khorana AA, Otten HM, Zwicker JI, Connolly GC, Farge-Bancel D, Pabinger I; Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. J Thromb Haemost. 2014 Nov;12(11):1928-31. doi: 10.1111/jth.12725.

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Büller HR. J Thromb Haemost. 2013 Jan;11(1):56-70. doi: 10.1111/jth.12070

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Büller HR, Bounameaux H.  J Thromb Haemost. 2013 Jan;11(1):71-80. doi: 10.1111/jth.12071.PMID: 23217208

Fever and deep venous thrombosis. Findings from the RIETE registry. Barba R, Di Micco P, Blanco-Molina A, Delgado C, Cisneros E, Villalta J, Morales MV, Bura-Riviere A, Debourdeau P, Monreal M. J Thromb Thrombolysis. 2011 Oct;32(3):288-92. doi: 10.1007/s11239-011-0604-7.

How to improve the implementation of guidelines on cancer-related thrombosis. Debourdeau P, Beckers M, Gérôme P, Durant C, Lacoin Q, Debourdeau A, Bancel DF. Expert Rev Anticancer Ther. 2011 Mar;11(3):473-83. Review.PMID:21417859.

Guidelines for good clinical practice: prevention and treatment of venous
thromboembolism in medical patients. Mismetti P, Baud JM, Becker F, Belmahdi F, Blanchard P, Constans J, Couturaud F, Debourdeau P, Drouet L, Dumarcet N, Ferrari E, Galanaud JP, Girard P, Hay B, Laporte S, Laroche JP, Leizorovicz A, Liard F, Mahé I, Meyer G, Oger E, Parent F,
Quéré I, Samama M; Agence française de sécurité sanitaire des produits de santé.
J Mal Vasc. 2010 Jun;35(3):127-36. doi:10.1016/j.jmv.2009.12.002.

2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. Farge D, Bosquet L, Kassab-Chahmi D, Mismetti P, Elalamy I, Meyer G, Cajfinger F, Desmurs-Clavel H, Elias A, Grange C, Hocini H, Legal G, Mahe I, Quéré I, Levesque H, Debourdeau P; SOR. Crit Rev Oncol Hematol. 2010 Jan;73(1):31-46.

Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients. Farge D, Durant C, Villiers S, Long A, Mahr A, Marty M, Debourdeau P; Groupe Francophone Thrombose et Cancer (GFTC). Thromb Res. 2010r;125 Suppl 2:S108-16.

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. Khorana AA, Streiff MB, Farge D, Mandala M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. J Clin Oncol. 2009 Oct 10;27(29):4919-26. doi: 10.1200/JCO.2009.22.3214.

2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. Debourdeau P, Kassab Chahmi D, Le Gal G, Kriegel I, Desruennes E, Douard MC, Elalamy I, Meyer G, Mismetti P, Pavic M, Scrobohaci ML, Lévesque H, Renaudin JM, Farge D; working group of the SOR. Ann Oncol. 2009 Sep;20(9):1459-1471. doi: 10.1093/annonc/mdp052.

Recommendations for venous thromboembolic events treatment and central venous catheter thrombosis management in cancer patients. Elias A, Debourdeau P, Renaudin JM, Desmurs-Clavel H, Mahé I, Elalamy I, Pavic M, Kassab-Chahmi D, Bosquet L, Cajfinger F, Desruennes E, Douard MC, Grange C, Hocini H, Kriegel I, Le Gal G, Meyer G, Mismetti P, Quéré I, Scrobohaci ML, Lévesque H, Farge-Bancel D. Presse Med. 2009 Feb;38(2):220-30. French. doi: 10.1016/j.lpm.2008.11.007.